Abstract
MiR-3614-5p has been found in a variety of cancers including colorectal cancer. However, the association of miR-3614-5p with colorectal cancer is still unclear. Based on the Cancer Genome Atlas (TCGA) database, the relationship between miR-3614-5p and colorectal cancer can be proved. Wilcoxon rank-sum test was used to compare the miR-3614-5p expression in colorectal cancer tissues and under normal conditions, respectively. The logistic regression method was further employed to analyze the relationship between miR-3614-5p and clinicopathological characteristics. Also, the correlation between miR-3614-5p and survival rate was evaluated by Kaplan-Meier and Cox regression analysis. Besides, gene set enrichment analysis (GSEA) was used to investigate the biological functions of miR-3614-5p. The decrease of miR-3614-5p expression of colorectal cancer was significantly correlated with N stage (OR) = 0.7 for N1&N2 vs. N0), M stage (OR = 0.5 for M1 vs. M0), pathologic stage (OR = 0.7 for Stage III & Stage IV vs. Stage I & Stage II), neoplasm type (OR = 0.5 for rectum adenocarcinoma vs. colon adenocarcinoma), and lymphatic invasion (OR = 0.6 for YES vs. NO) (all p-values < 0.05). Kaplan-Meier survival analysis showed that colorectal cancer with low miR-3614-5p has a poorer prognosis than that of high miR-3614-5p (p = 0.005). According to univariate analysis, low miR-3614-5p was associated with poor overall survival (OS) [hazard ratio (HR) = 0.599; 95% confidence interval (CI): 0.418-0.857; p = 0.005]. In multivariate analysis, miR-3614-5p was closely related to OS (HR = 0.630; 95% CI: 0.405-0.978, p = 0.021). GSEA showed that the high expression phenotype of miR-3614-5p differentially enriches the P53 pathway. Meanwhile, the high expression phenotype of miR-3614-5p enhanced NK T cell activation, negative T cell selection, response to interleukin 2, and response to tumor cells. MiR-3614-5p is a possible prognostic marker of low survival rate for patients with colorectal cancer. Moreover, the P53 pathway and P38MAPK pathway may be the key pathways regulated by miR-3614-5p in colorectal cancer.
Highlights
Colorectal cancer (CRC), a common malignant tumor in the gastrointestinal tract/intestine or large intestine, is a major threat to health around the globe
Following the statistical analysis of the pathologic stage, patients with stage I accounted for 17.5% (n = 102), while 37.1% (n = 216), 30.1% (n = 175), and 15.3% (n = 89) patients were in stage II, III, and IV, respectively
Decreased expression of miR-36145p in CRC was related to the following factors: N stage (OR of N1 and N2 and N0 = 0.7), M stage (OR of M1 and M0 = 0.5), pathological stage (OR of stage III and IV = 0.7 and I Stage and II), tumor type (OR of rectal adenocarcinoma and colon adenocarcinoma = 0.5), and lymphatic infiltration (OR of YES vs. NO = 0.6). These results indicate that compared with people with high miR3614-5p expression, people with low miR-3614-5p expression are more likely to enter the late stage and may have a lymphatic invasion
Summary
Colorectal cancer (CRC), a common malignant tumor in the gastrointestinal tract/intestine or large intestine, is a major threat to health around the globe. CRC is the fourth fatal cancer and causes nearly 900,000 deaths annually worldwide. Through quantitative analysis of CRC estimates that mutation from stem cells to malignant cells happens at first. It takes some time for these tumor cells to acquire metastatic ability. The 5-year survival rate of stage IV is less than 10% (Chuang et al, 2017; Bora et al, 2021). Surgery remains to be the primary clinical treatment, supplemented by chemotherapy and immunotherapy. The efficacy of these treatments remains poor for the advanced stage of the disease. There is great urgency to develop new diagnostic and therapeutic targets
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
